Ouathek Ouerfelli

Retraction to: Nature https://doi.org/10.1038/s41586-025-09727-z Published online 26 November 2025 The Editors have retracted this article at the Authors’ request. After publication, concerns were raised regarding the tumour burden in some mice in the control arms of the experiments presented in Fig. 4b (NPPO1-NE, NPPO-4, NPPO-6, and MSKPCa10 grafts) and Fig. 5j (WCM1262 grafts).

Abstract Lineage plasticity is a cancer hallmark that drives disease progression and treatment resistance1,2. Plasticity is often mediated by epigenetic mechanisms that may be reversible; however, there are few examples of such reversibility. In castration-resistant prostate cancer (CRPC), plasticity mediates resistance to androgen receptor (AR) inhibitors and progression from adenocarcinoma to aggressive subtypes, including neuroendocrine prostate cancer (CRPC-NE)3,4,5.

Main text (Cancer Cell 36, 139–155.e1–e10, August 12, 2019) We, the authors of the publication, reported that epigenetic reprogramming by the Polycomb repressive complex 1 (PRC1) promotes an immunosuppressive tumor microenvironment in double-negative prostate cancer in mouse models. We have identified some errors in the published figures.